Taking full advantage of Canada's favorable regulatory landscape, Altasciences’ clinical facility in Montréal continues to be a popular choice, successfully completing hundreds of clinical trials each year.

In this issue of The Altascientist, we discuss the distinct benefits of conducting early phase clinical research on novel compounds in Canada versus other countries.  

 
DOWNLOAD NOW 

We cover:
•    Canadian CTA trials–time and cost savings
•    regulatory review process predictability
•    business efficiency cost savings
•    clinical trial participants
•    Canadian CTA frequently asked questions
 

You may also be interested in the following resources: 

Webpage: Altasciences' Three Clinical Trial Facilities

Videos:

• Accelerate Your Data With Altasciences’ Co-located Clinic and Lab
• Canada’s Regulatory Requirements for CTA Filings

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programmes, to offer an integrated/synchronised approach to CRO and CDMO services.

Watch this podcast in which Altasciences' regulatory experts share key insights on Health Canada's Clinical Trial Application (CTA) regulatory submission process, including answers to your most common questions.

Altasciences’ Canadian clinical facility consists of seven Phase I units. We conduct over 100 trials every year in Canada, and support the full range of first-in-human studies, specialty studies, and therapeutic areas, such as ophthalmology, CNS, and substance abuse.

Take five minutes to explore these insightful resources: 

• The Altascientist: The Advantages of Conducting Early Phase Clinical Research in Canada 
• ​​​​​Videos: 
  • Step Inside Altasciences' Canadian Early Phase Clinical Facility 
  • Canadian Clinical Facility Only a 15-Minute Drive From Lab

Safe Strategy to Save Time and Money 

Avoid repeating Phase I studies for drugs intended for the Asian market. Altasciences has the clinical capabilities to demonstrate the biosimilarity of drug products between Asian and non-Asian populations by comparing the pharmacokinetics of the investigational drug in both ethnic groups, providing a safe strategy to save time and money. 

Key resources for ethnobridging in Phase I clinical trials: 

In this issue of The Altascientist, we demonstrate how ethnobridging can prevent the need for region-specific development programs, helping you safely achieve commercial milestones more efficiently. Download your copy today. 

In this complimentary webinar, Mel B. Affrime, PharmD, Executive Vice President, Translational Medicine, discusses how ethnic differences can impact the bioavailability of your drug candidate and how to design a multiregional clinical development program to hasten worldwide regulatory approval safely. Watch the webinar.

Speak with an expert today to discuss your next clinical program. 

You may also be interested in the following webpages:​​​ 

• Ethnobridging Clinical Trials 
• Early Clinical Development Services — Phase I/II 

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.

Experience You Can Count On

With over 25 years of experience, Altasciences offers pain stimulation models and pharmacodynamics tests for early phase analgesic trials. These tests provide critical data for informed decision-making. Our team of pain experts and neuroscientists is here to assist you in selecting the most appropriate pain model to successfully evaluate your study drug's efficacy and safety profile.

Discover how we can deliver the solutions needed for your pain research.

DOWNLOAD THE FACT SHEET

You may also be interested in the following resources:

• Webinar: How Questionnaires, Models, and Tests of Cognition Can Accelerate the Development of CNS-Active Drugs
• Pain Model Poster: Inside the Pharmacodynamic Toolbox

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

Get Ahead of the Competition

Looking to take your ex-U.S. strategy to the next level? With a state-of-the-art clinical facility in Canada, Altasciences has the capacity and decades of expertise to submit your CTA six to nine weeks earlier than an IND.

We can help get you into the clinic faster—schedule a chat today!

Must-watch videos:

	Co-located Canadian Ophthalmology Center for All Your Early Phase Development Needs
	Accelerate Your Data With Our Canadian Co-located Clinic and Lab
	Montréal Clinic Mini Tour

Altasciences Ophthalmic Clinical Offering: A Unique Integration of Expertise, Location, and Passion

At Altasciences, we understand the unique challenges of developing treatments for retinal disease. That's why we've created an integrated approach that brings together clinical and scientific expertise specific to ophthalmology. From our state-of-the-art equipment, streamlined processes, to a co-located ophthalmic clinic, every element of our offering is designed to help move treatments forward and improve patient outcomes. 

Watch as Dr. William Foster, Retinal Specialist and Principal Investigator, explains why Altasciences is the ideal partner for your ophthalmic clinical trials.

Speak with our experts to discuss your ophthalmic drug development needs.

Have five minutes? Take a look at these resources: 

Webpages:

• End-To-End Ophthalmic Drug Development Services
• Clinical Research Services

Scientific Journal: Navigating the Complexities of Ophthalmic Drug Development
 

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.